{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Femring%C2%AE",
    "query": {
      "intervention": "Femring®"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 98,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Femring%C2%AE&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T11:06:36.516Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03294538",
      "title": "Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrophic Vaginitis"
      ],
      "interventions": [
        {
          "name": "Generic Estradiol Vaginal Cream USP, 0.01%",
          "type": "DRUG"
        },
        {
          "name": "Estrace® Vaginal Cream USP, 0.01%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Vaginal Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 75 Years · Female only"
      },
      "enrollment_count": 663,
      "start_date": "2016-05-18",
      "completion_date": "2017-02-15",
      "has_results": true,
      "last_update_posted_date": "2019-12-26",
      "last_synced_at": "2026-09-07T11:06:36.516Z",
      "location_count": 44,
      "location_summary": "Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03294538"
    },
    {
      "nct_id": "NCT01344369",
      "title": "Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Norethindrone/Ethinyl Estradiol",
          "type": "DRUG"
        },
        {
          "name": "FEMCON® Fe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 36,
      "start_date": "2008-08",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2011-05-30",
      "last_synced_at": "2026-09-07T11:06:36.516Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01344369"
    },
    {
      "nct_id": "NCT01165307",
      "title": "Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Menorrhagia"
      ],
      "interventions": [
        {
          "name": "Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills",
          "type": "DRUG"
        },
        {
          "name": "Naproxen sodium pills",
          "type": "DRUG"
        },
        {
          "name": "NovaSure® Radiofrequency Endometrial Ablation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Abimbola Famuyide",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 55 Years · Female only"
      },
      "enrollment_count": 77,
      "start_date": "2009-08",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-01-20",
      "last_synced_at": "2026-09-07T11:06:36.516Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01165307"
    },
    {
      "nct_id": "NCT05739136",
      "title": "MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pregnancy Related",
        "Pregnancy Complications",
        "Pregnancy, High Risk"
      ],
      "interventions": [
        {
          "name": "Relugolix + Estradiol + Norethindrone Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma Switzerland GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 530,
      "start_date": "2025-04-30",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2025-08-01",
      "last_synced_at": "2026-09-07T11:06:36.516Z",
      "location_count": 1,
      "location_summary": "Marlborough, Massachusetts",
      "locations": [
        {
          "city": "Marlborough",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05739136"
    },
    {
      "nct_id": "NCT00889512",
      "title": "The Luveris In Vitro Fertilization Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infertility",
        "Hypothalamic Amenorrhea",
        "Hyperprolactinemia"
      ],
      "interventions": [
        {
          "name": "Luveris fixed dose",
          "type": "DRUG"
        },
        {
          "name": "Luveris increasing dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Reproductive Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "38 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 38 Years · Female only"
      },
      "enrollment_count": 14,
      "start_date": "2009-04",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2018-08-07",
      "last_synced_at": "2026-09-07T11:06:36.516Z",
      "location_count": 1,
      "location_summary": "Hasbrouck Heights, New Jersey",
      "locations": [
        {
          "city": "Hasbrouck Heights",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00889512"
    },
    {
      "nct_id": "NCT07544966",
      "title": "Teen Vulnerability to Irritability: Brain and Estrogen Changes",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depression - Major Depressive Disorder",
        "Irritability"
      ],
      "interventions": [
        {
          "name": "Kurvelo",
          "type": "DRUG"
        },
        {
          "name": "Placebo COC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "16 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 16 Years · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2026-10-01",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-09-07T11:06:36.516Z",
      "location_count": 2,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07544966"
    },
    {
      "nct_id": "NCT01182194",
      "title": "Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Drospirenone/Ethinyl Estradiol (Gianvi®)",
          "type": "DRUG"
        },
        {
          "name": "YAZ®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 32,
      "start_date": "2006-06",
      "completion_date": "2006-08",
      "has_results": true,
      "last_update_posted_date": "2010-12-08",
      "last_synced_at": "2026-09-07T11:06:36.516Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01182194"
    },
    {
      "nct_id": "NCT06997029",
      "title": "A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Advanced Breast Cancer",
        "Advanced Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "BMS-986500",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2025-08-01",
      "completion_date": "2028-12-14",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-09-07T11:06:36.516Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Fullerton, California • Greenbrae, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06997029"
    },
    {
      "nct_id": "NCT01953588",
      "title": "Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Estrogen Receptor-positive Breast Cancer",
        "HER2-negative Breast Cancer",
        "Invasive Ductal Breast Carcinoma",
        "Invasive Lobular Breast Carcinoma",
        "Recurrent Breast Cancer",
        "Stage II Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer"
      ],
      "interventions": [
        {
          "name": "fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "anastrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1473,
      "start_date": "2014-02-27",
      "completion_date": "2027-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-09-07T11:06:36.516Z",
      "location_count": 856,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 524 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01953588"
    },
    {
      "nct_id": "NCT02195986",
      "title": "A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrophic Vaginitis"
      ],
      "interventions": [
        {
          "name": "Estradiol Vaginal Cream, 0.01%",
          "type": "DRUG"
        },
        {
          "name": "Estrace® 0.01% cream",
          "type": "DRUG"
        },
        {
          "name": "Placebo Vaginal Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 70 Years · Female only"
      },
      "enrollment_count": 366,
      "start_date": "2014-06",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2022-03-09",
      "last_synced_at": "2026-09-07T11:06:36.516Z",
      "location_count": 21,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02195986"
    }
  ]
}